ArticleMolecular medicine reports2026
Exploring the role of cytochrome P450 family 1 subfamily B member 1 and quercetin in modulating neuropathic pain after spinal cord injury.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Arachidonic acid metabolism in spinal cord injury.Journal of advanced research · 2026Review
- Integrated machine learning and multi-omics analysis identifies CYP1B1 as a candidate target of orientin in intervertebral disc degeneration-associated low back pain.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- From multi-target mechanisms to clinical translation: the analgesic potential of quercetin.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) represents a notable global health challenge, with neuropathic pain (NP) being a common complication that intensifies patient suffering. Existing research tends to overlook the temporal aspects of NP and fails to offer targeted treatment options. To tackle this issue, the present study initially examined genome‑wide association study summaries related to NP, incorporating expression quantitative trait locus (eQTL) from blood samples through summary‑based Mendelian randomization. This allowed the investigation of the association between NP and eQTL, facilitating the identification of genes linked to the risk of NP. Following this, weighted gene co‑expression network analysis of a Gene Expression Omnibus dataset was utilized to identify SCI‑related module genes, resulting in the detection of 218 shared genes across these analyses. Subsequent functional enrichment assessments, protein‑protein interaction evaluations and machine learning technique analyses, including least absolute shrinkage and selection operator regression, random forest and support vector machine recursive feature elimination analyses, highlighted three central genes: Glycerol‑3‑phosphate dehydrogenase 1‑like, epoxide hydrolase 2 and cytochrome P450 family 1 subfamily B member 1 (CYP1B1). Additionally, network pharmacology and molecular docking analyses confirmed CYP1B1 as a viable therapeutic target. A analysis of single‑cell RNA sequencing datasets demonstrated an increase in CYP1B1 expression within spinal cord fibroblasts following SCI. Furthermore, quercetin (Que) was shown to inhibit CYP1B1 expression and reduce NP (based on mechanical paw withdrawal threshold and thermal paw withdrawal latency) in murine models. The results of the present study highlight the important role of spinal cord fibroblast CYP1B1 as a notable contributor to NP following SCI and suggest that Que may serve as a promising mechanism‑based therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.